Or Rabinowitz Batz
Visiting Associate Professor
Center for International Security and Cooperation
Academic Appointments
-
Visiting Associate Professor, Center for International Security and Cooperation
2023-24 Courses
- Israel, the Middle East and Nuclear Weapons
POLISCI 115B (Aut) -
Prior Year Courses
2022-23 Courses
- Israel, the Middle East and Nuclear Weapons
POLISCI 115B (Aut)
- Israel, the Middle East and Nuclear Weapons
All Publications
-
Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review
Frontiers in Neurology
2022; 13
View details for DOI 10.3389/fneur.2022.806344
-
Partnering with a senior living community to optimize teledermatology via full body skin screening during the COVID-19 pandemic: a pilot program
Skin Health and Disease
2022
View details for DOI 10.1002/ski2.141
-
Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy
The Neurohospitalist
2021: 74-79
Abstract
Axicabtagene ciloleucel (AC) is an FDA-approved anti-CD19 autologous chimeric antigen receptor T-cell (CAR-T) therapy for refractory diffuse large B cell lymphoma (DLBCL). While its efficacy in DLBCL has been promising, neurotoxicity remains a significant concern. We present a case of a 22-year-old woman with chemotherapy-refractory DLBCL who exhibited Grade IV neurotoxicity in the setting of sepsis, after undergoing AC infusion. Despite prophylactic levetiracetam given per guidelines,1,2 she experienced a precipitous mental status decline on post-infusion day 8 (D8) followed by hypoxic respiratory failure in the setting of clinical status epilepticus on D11 and nonconvulsive status epilepticus (NCSE) on D18. While neuroimaging was unremarkable, EEG demonstrated diffuse slowing and 2.5-3 Hz generalized periodic discharges consistent with NCSE. Seizures were initially refractory to lorazepam, increasing doses of levetiracetam, and phenobarbital, requiring a midazolam drip titrated to 50-70% burst suppression for resolution. Methylprednisolone and tocilizumab were used to treat neurotoxicity and cytokine release syndrome, respectively. Empiric antibiotics were used for sepsis. After cessation of sedatives on D19, mental status improved to near baseline. PET/CT just prior to discharge showed a complete response of the DLBCL (Deauville 3). She was discharged on D37 with no further seizure activity. Unfortunately, a 3-month interval PET/CT demonstrated disease progression which continued through salvage pembrolizumab eventually leading to death 1.2 years post-CAR-T infusion. This case illustrates the clinical management challenges of a complex and rare neurotoxic side effect of CAR-T cell therapy, namely NCSE following status epilepticus.
View details for DOI 10.1177/19418744211000980
View details for PubMedCentralID PMC8689529
-
Cross-Species Transmission of Coronaviruses in Humans and Domestic Mammals, What Are the Ecological Mechanisms Driving Transmission, Spillover, and Disease Emergence?
Frontiers in Public Health
2021; 9: 717941
View details for DOI 10.3389/fpubh.2021.717941
-
Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
JCO Precision Oncology
2021; 5: 1073-81
View details for DOI 10.1200/PO.20.00484
-
Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing
JCO Precision Oncology
2021; 5: 307-316
View details for DOI 10.1200/PO.20.00246
-
Association of collective attitudes and contraceptive practice in nine sub-Saharan African countries
Journal of Global Health
2020; 10 (1)
View details for DOI 10.7189/jogh.10.010705
-
Measuring aspects of high-reliability culture in healthcare settings
J Pt Saf Risk Manag
2019
View details for DOI 10.1177/2516043519838185
-
Minimally Invasive Lumbar Pedicle Screw Fixation Using Cortical Bone Trajectory: Functional Outcomes
Cureus
2018; 10(10): e3462
View details for DOI 10.7759/cureus.3462
-
Postmortem Somatic Sequencing of Tumors From Patients With Suspected Lynch Syndrome Has Clinical Utility for Surviving Relatives
JCO Precision Oncology
2018; 2 (1): 1-7
View details for DOI 10.1200/PO.18.00108
View details for PubMedCentralID PMC7446443